Hypoxia-Related LncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Oct 18

PMID 34659218

Citations 24

Authors

Shengchao Xu

Lu Tang

Zhixiong Liu

Chengke Luo

Quan Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Hypoxia-related genes are demonstrated to correlate with the prognosis of various cancers. However, the role of hypoxia-related long non-coding RNAs (HRLs) in lower-grade glioma (LGG) remains unclear.

Methods: A total of 700 LGG samples were extracted from TCGA and CGGA databases. Pearson correlation analysis was used to identify HRLs. Lasso analysis was adopted to construct the HRL signature. TIDE algorithm was used to predict responses to immune checkpoint inhibitors. Cell proliferation was estimated by cell counting kit-8 assay, colony formation assay, and EdU assay.

Results: We identified 340 HRLs and constructed a novel risk signature composed of 19 HRLs. The risk score exhibited potent value in predicting the prognosis of LGG patients and was significantly associated with the prognosis of LGG patients. Moreover, HRL signature could distinguish patients with similar expression levels of immune checkpoints and might predict the efficacy of immune checkpoint inhibitors. Additionally, hypoxia-related pathways and immune pathways were enriched in high-risk group, and high risk score indicated low tumor purity and high immune infiltration. Two major HRLs, LINC00941 and BASP1-AS1, could significantly affect the proliferation of glioma cells.

Conclusions: Our study constructed a novel HRL signature that could predict the prognosis and immunotherapy response of LGG patients. HRLs could be novel biomarkers to predict the prognosis of LGG patients and potential targets for LGG treatment.

Citing Articles

Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression.

Sabit H, Arneth B, Abdel-Ghany S, Madyan E, Ghaleb A, Selvaraj P Cells. 2024; 13(19).

PMID: 39404428 PMC: 11475877. DOI: 10.3390/cells13191666.

Chen Y, Chen S, Wu Z, Cheng Q, Ji D Cancer Cell Int. 2024; 24(1):336.

PMID: 39385179 PMC: 11465649. DOI: 10.1186/s12935-024-03509-9.

Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.

Yang J, Shen L, Yang J, Qu Y, Gong C, Zhou F Transl Cancer Res. 2024; 13(1):112-136.

PMID: 38410234 PMC: 10894340. DOI: 10.21037/tcr-23-906.

Selection of M7G-related lncRNAs in kidney renal clear cell carcinoma and their putative diagnostic and prognostic role.

Zhong S, Chen S, Lin H, Luo Y, He J BMC Urol. 2023; 23(1):186.

PMID: 37968670 PMC: 10652602. DOI: 10.1186/s12894-023-01357-9.

Machine learning-based identification of lower grade glioma stemness subtypes discriminates patient prognosis and drug response.

Zhou H, Chen B, Zhang L, Li C Comput Struct Biotechnol J. 2023; 21:3827-3840.

PMID: 37560125 PMC: 10407594. DOI: 10.1016/j.csbj.2023.07.029.

References

Zhang X, Shi M, Chen T, Zhang B . Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020; 22:298-309. PMC: 7522342. DOI: 10.1016/j.omtn.2020.08.030. View

Li Y, Shen R, Wang A, Zhao J, Zhou J, Zhang W . Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma. Front Cell Dev Biol. 2021; 9:648806. PMC: 8044985. DOI: 10.3389/fcell.2021.648806. View

Xiao K, Tan J, Yuan J, Peng G, Long W, Su J . Prognostic value and immune cell infiltration of hypoxic phenotype-related gene signatures in glioblastoma microenvironment. J Cell Mol Med. 2020; 24(22):13235-13247. PMC: 7701576. DOI: 10.1111/jcmm.15939. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

Smoll N, Gautschi O, Schatlo B, Schaller K, Weber D . Relative survival of patients with supratentorial low-grade gliomas. Neuro Oncol. 2012; 14(8):1062-9. PMC: 3408266. DOI: 10.1093/neuonc/nos144. View

Ohgaki H, Kleihues P . Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005; 64(6):479-89. DOI: 10.1093/jnen/64.6.479. View

Shen Y, Peng X, Shen C . Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020; 112(3):2640-2646. DOI: 10.1016/j.ygeno.2020.02.015. View

Eustace A, Mani N, Span P, Irlam J, Taylor J, Betts G . A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res. 2013; 19(17):4879-88. PMC: 3797516. DOI: 10.1158/1078-0432.CCR-13-0542. View

Yang L, Taylor J, Eustace A, Irlam J, Denley H, Hoskin P . A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. Clin Cancer Res. 2017; 23(16):4761-4768. DOI: 10.1158/1078-0432.CCR-17-0038. View

10.

Wu J, Su H, Yu Z, Xi S, Guo C, Hu Z . Skp2 modulates proliferation, senescence and tumorigenesis of glioma. Cancer Cell Int. 2020; 20:71. PMC: 7059397. DOI: 10.1186/s12935-020-1144-z. View

11.

Havel J, Chowell D, Chan T . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019; 19(3):133-150. PMC: 6705396. DOI: 10.1038/s41568-019-0116-x. View

12.

Mo Z, Yu L, Cao Z, Hu H, Luo S, Zhang S . Identification of a Hypoxia-Associated Signature for Lung Adenocarcinoma. Front Genet. 2020; 11:647. PMC: 7324800. DOI: 10.3389/fgene.2020.00647. View

13.

Jiang T, Nam D, Ram Z, Poon W, Wang J, Boldbaatar D . Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2020; 499:60-72. DOI: 10.1016/j.canlet.2020.10.050. View

14.

Gibney G, Weiner L, Atkins M . Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016; 17(12):e542-e551. PMC: 5702534. DOI: 10.1016/S1470-2045(16)30406-5. View

15.

Zhang Y, Yang M, Ng D, Haleem M, Yi T, Hu S . Multi-omics Data Analyses Construct TME and Identify the Immune-Related Prognosis Signatures in Human LUAD. Mol Ther Nucleic Acids. 2020; 21:860-873. PMC: 7452010. DOI: 10.1016/j.omtn.2020.07.024. View

16.

Wang R, Gurguis C, Gu W, Ko E, Lim I, Bang H . Ion channel gene expression predicts survival in glioma patients. Sci Rep. 2015; 5:11593. PMC: 4522676. DOI: 10.1038/srep11593. View

17.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

18.

Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L . Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021; 40(1):184. PMC: 8178863. DOI: 10.1186/s13046-021-01987-7. View

19.

Wang Y, Wang Y, Xu C, Liu Y, Huang Z . Identification of Novel Tumor-Microenvironment-Regulating Factor That Facilitates Tumor Immune Infiltration in Colon Cancer. Mol Ther Nucleic Acids. 2020; 22:236-250. PMC: 7515980. DOI: 10.1016/j.omtn.2020.08.029. View

20.

Ruan X, Zheng J, Liu X, Liu Y, Liu L, Ma J . lncRNA LINC00665 Stabilized by TAF15 Impeded the Malignant Biological Behaviors of Glioma Cells via STAU1-Mediated mRNA Degradation. Mol Ther Nucleic Acids. 2020; 20:823-840. PMC: 7256440. DOI: 10.1016/j.omtn.2020.05.003. View